So far over 100 experts from friendly neighboring nations have been trained to build capacity in their countries to facilitate India’s Phase 3 clinical trials COVID-19 vaccine, a senior biotechnology department official said Wednesday. Speaking at a webinar organized by the Confederation of Indian Industry, Alka Sharma, a consultant to the Department of Biotechnology, said that the Partnership for the Advancement of the Clinical Trials Initiative (PACT) is being carried out in association with the Ministry of Foreign Affairs.
“… PACT is under the initiative of the Department of Biotechnology and Ministry of Foreign Affairs to strengthen capacities to facilitate Phase 3 clinical trials of the Indian COVID vaccine in friendly neighboring countries,” he said. As part of this initiative, two training modules have been successfully completed so far.
“More than 100 participants from Afghanistan, Bhutan, Maldives, Mauritius, Nepal, Sri Lanka took part in this training program,” he said. The plan is to have the next round of the training program with a larger number of participants, he added. He said that currently 30 groups are actively involved in the development of coronavirus vaccine. Six vaccines are in various stages of clinical trials, of which four are in local development, he said. Sharma said Bharat Biotech’s clinical pathways are in phase 3, while the one developed by Zydus Cadila is in phase 2 clinical trials.
Biological E vaccine candidate is in Phase 1 clinical trials, while Gennovabiopharmaceuticals is in the process of gaining approvals at various levels. The Serum Institute of India (SII) is also conducting Phase 2 and 3 clinical trials of the Oxford-Astrazeneca vaccine. Similarly, Dr Reddy’s labs are conducting phase 2 and 3 clinical trials for the Russian Sputnik V vaccine, he said.